title: Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate.
authors.forename: G
authors.initials: G
authors.lastname: LeMarbre
authors.forename: C
authors.initials: C
authors.lastname: Schinstock
authors.forename: R
authors.initials: R
authors.lastname: Hoyer
authors.forename: J
authors.initials: J
authors.lastname: Krook
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000188:drug therapy; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007136:Immunoglobulins / Q000008:administration & dosage; D007275:Injections, Intravenous; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011241:Prednisone / Q000008:administration & dosage; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D007136:Immunoglobulins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011241:Prednisone